Clinical Research Directory
Browse clinical research sites, groups, and studies.
Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure
Sponsor: King Edward Medical University
Summary
This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function tests).
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
62
Start Date
2026-07-16
Completion Date
2026-10-17
Last Updated
2026-08-19
Healthy Volunteers
No
Conditions
Interventions
N Acetyl Cysteine
Oral or nasogastric N-acetylcysteine administered at 140 mg/kg every 4 hours for the first 16 hours, followed by 140 mg/kg every 6-8 hours, continued for a total duration of 3 days, given in addition to standard supportive care.
Standard supportive care
Standard supportive care protocol for acute liver failure (glucose control, antimicrobials, PPIs, fluid/electrolyte management, anti-encephalopathy measures, FFP as needed).
Locations (1)
King Edward Medical University/Mayo Hospital Lahore
Lahore, Punjab Province, Pakistan